Sphingosine-1-phosphate in Asthma

NCT04134351 | Unknown

• 1 other identifier: 223069
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

This study is being undertaken in order to enhance our understanding how human airways are being constricted in healthy people and in individuals with asthma. There is an unmet need for identification of new pathways (mediators) related to enhanced constriction of the asthmatic airways that would reveal new targets for therapy. Sphingosine-1-phosphate (S1P) is a naturally occurring bioactive lipid molecule that has been suggested to play an important role in asthma. Physiologically, S1P can be detected in human blood but local tissue concentrations (for example in the lung) are very low. Upon activation many cells can secrete S1P. Increased concentrations of S1P have been detected in airways of asthmatic subjects after allergen inhalation. When studied in animal models, S1P did not cause contraction of airways in healthy animals but contracted airways in animal with pulmonary inflammation. In laboratory experiments S1P has been shown to be a potent constrictor of cells responsible for contraction of human airways. As yet, however, we lack evidence that S1P actually causes constriction of airways in real life. Establishing S1P as a molecule capable of causing airway constriction in humans and perhaps specifically in asthmatics will have important implications for our understanding of physiological and pathophysiological responses in human airways and could open new windows for therapeutic strategies in diseases like asthma.

Conditions

Asthma

Outcome Measures

Primary Outcomes (1)

• Bronchoconstriction

  Bronchoconstriction in response to challenge measured by spirometry (FEV1)(PC20)

  1 hour after challenge

Interventions

Bronchial challenge test OTHER

Bronchial challenge test with sphingosine-1-phosphate

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Physician diagnosed asthma, defined as a clear history of typical symptoms and clear reversibility of the PEF/FEV1 (12% or more) within the past year and/or methacholine PC20 \< 8mg/ml.

You may not qualify if:

• Pregnancy or lactation
• Moderate / Severe asthma (FEV1/PEF \< 80%of the predicted value at screening)
• Patients with any chronic illness other than asthma and other recognised atopic diseases (eczema, rhinitis) or any other abnormality which in the opinion of the principal investigator might compromise the study findings
• A history of recent (within the past 4 weeks) upper or lower respiratory tract infection
• Patients receiving oral, inhaled or parenteral glucocorticoid therapy (steroid) within the last 4 weeks, long acting relievers (salmeterol, formoterol) and antileukotrienes (montelukast) within last 72 hours.
• Inadequate contraception in women of childbearing age
• Inability to comprehend or comply with the protocol
• \. Lifelong absence of asthma symptoms and lung function within the normal range.
• Pregnancy or lactation
• Patients with any chronic illness or any other abnormality which in the opinion of the principal investigator might compromise the study findings
• A history of recent (within the past 4 weeks) upper or lower respiratory tract infection
• Oral, inhaled or parenteral glucocorticoid therapy (steroid) within the last 4 weeks, long acting relievers (salmeterol, formoterol) and antileukotrienes (montelukast) within last 72 hours
• Inadequate contraception in women of childbearing age
• Inability to comprehend or comply with the protocol

Sponsors & Collaborators

• Guy's and St Thomas' NHS Foundation Trust: lead
• King's College London: collaborator

Study Sites (1)

Allergy Day Care Unite, Guy's Hospital

London, SE1 9RT, United Kingdom

RECRUITING

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Grzegorz Woszczek, MD, PhD

  King's College London

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Grzegorz Woszczek, MD, PhD

CONTACT

+44 2071880597; grzegorz.woszczek@kcl.ac.uk

Leonard Siew, MRCP, PhD

CONTACT

leonard.siew@gstt.nhs.uk

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 18, 2019
• First Posted: October 22, 2019
• Study Start: February 4, 2020
• Primary Completion: February 22, 2022
• Study Completion: February 22, 2022
• Last Updated: July 28, 2021

Record last verified: 2021-07

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)